These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

174 related items for PubMed ID: 2508092

  • 1. Role of thrombin and thromboxane A2 in reocclusion following coronary thrombolysis with tissue-type plasminogen activator.
    Fitzgerald DJ, Fitzgerald GA.
    Proc Natl Acad Sci U S A; 1989 Oct; 86(19):7585-9. PubMed ID: 2508092
    [Abstract] [Full Text] [Related]

  • 2. Increased thromboxane biosynthesis during coronary thrombolysis. Evidence that platelet activation and thromboxane A2 modulate the response to tissue-type plasminogen activator in vivo.
    Fitzgerald DJ, Wright F, FitzGerald GA.
    Circ Res; 1989 Jul; 65(1):83-94. PubMed ID: 2500270
    [Abstract] [Full Text] [Related]

  • 3. Combination of inhibition of thrombin and blockade of thromboxane A2 synthetase and receptors enhances thrombolysis and delays reocclusion in canine coronary arteries.
    Yao SK, Ober JC, Ferguson JJ, Anderson HV, Maraganore J, Buja LM, Willerson JT.
    Circulation; 1992 Dec; 86(6):1993-9. PubMed ID: 1451271
    [Abstract] [Full Text] [Related]

  • 4. Comparative effects of aspirin, a synthetic thrombin inhibitor and a monoclonal antiplatelet glycoprotein IIb/IIIa antibody on coronary artery reperfusion, reocclusion and bleeding with recombinant tissue-type plasminogen activator in a canine preparation.
    Yasuda T, Gold HK, Yaoita H, Leinbach RC, Guerrero JL, Jang IK, Holt R, Fallon JT, Collen D.
    J Am Coll Cardiol; 1990 Sep; 16(3):714-22. PubMed ID: 2117620
    [Abstract] [Full Text] [Related]

  • 5. Endogenous prostaglandin endoperoxides and prostacyclin modulate the thrombolytic activity of tissue plasminogen activator. Effects of simultaneous inhibition of thromboxane A2 synthase and blockade of thromboxane A2/prostaglandin H2 receptors in a canine model of coronary thrombosis.
    Golino P, Rosolowsky M, Yao SK, McNatt J, De Clerck F, Buja LM, Willerson JT.
    J Clin Invest; 1990 Oct; 86(4):1095-102. PubMed ID: 2145320
    [Abstract] [Full Text] [Related]

  • 6. Interaction of a thrombin inhibitor and a platelet GP IIb/IIIa antagonist in vivo: evidence that thrombin mediates platelet aggregation and subsequent thromboxane A2 formation during coronary thrombolysis.
    Pratico D, Murphy NP, Fitzgerald DJ.
    J Pharmacol Exp Ther; 1997 Jun; 281(3):1178-85. PubMed ID: 9190851
    [Abstract] [Full Text] [Related]

  • 7. Mediation of reocclusion by thromboxane A2 and serotonin after thrombolysis with tissue-type plasminogen activator in a canine preparation of coronary thrombosis.
    Golino P, Ashton JH, Glas-Greenwalt P, McNatt J, Buja LM, Willerson JT.
    Circulation; 1988 Mar; 77(3):678-84. PubMed ID: 3124975
    [Abstract] [Full Text] [Related]

  • 8. Oxygen radical scavenging agents as adjuvant therapy with tissue plasminogen activator in a canine model of coronary thrombolysis.
    Przyklenk K, Kloner RA.
    Cardiovasc Res; 1993 Jun; 27(6):925-34. PubMed ID: 8221780
    [Abstract] [Full Text] [Related]

  • 9. Enhancement of thrombolytic efficacy of tissue-type plasminogen activator by adjuvants in the guinea pig thrombosis model.
    Nishiyama H, Umemura K, Saniabadi AR, Takiguchi Y, Uematsu T, Nakashima M.
    Eur J Pharmacol; 1994 Oct 24; 264(2):191-8. PubMed ID: 7851482
    [Abstract] [Full Text] [Related]

  • 10. Relative efficacy of antithrombin compared with antiplatelet agents in accelerating coronary thrombolysis and preventing early reocclusion.
    Haskel EJ, Prager NA, Sobel BE, Abendschein DR.
    Circulation; 1991 Mar 24; 83(3):1048-56. PubMed ID: 1900222
    [Abstract] [Full Text] [Related]

  • 11. Aspirin does not potentiate effect of suboptimal dose of the thrombin inhibitor inogatran during coronary thrombolysis.
    Chen LY, Nichols WW, Mattsson C, Teger-Nilson AC, Wallin R, Saldeen TG, Mehta JL.
    Cardiovasc Res; 1995 Dec 24; 30(6):866-74. PubMed ID: 8746200
    [Abstract] [Full Text] [Related]

  • 12. Simultaneous administration of thromboxane A2- and serotonin S2-receptor antagonists markedly enhances thrombolysis and prevents or delays reocclusion after tissue-type plasminogen activator in a canine model of coronary thrombosis.
    Golino P, Ashton JH, McNatt J, Glas-Greenwalt P, Yao SK, O'Brien RA, Buja LM, Willerson JT.
    Circulation; 1989 Apr 24; 79(4):911-9. PubMed ID: 2494005
    [Abstract] [Full Text] [Related]

  • 13. Prevention of reocclusion by MCI-9038, a thrombin inhibitor, following t-PA-induced thrombolysis in a canine model of femoral arterial thrombosis.
    Mellott MJ, Connolly TM, York SJ, Bush LR.
    Thromb Haemost; 1990 Dec 28; 64(4):526-34. PubMed ID: 2128137
    [Abstract] [Full Text] [Related]

  • 14. A prostacyclin analog impairs the response to tissue-type plasminogen activator during coronary thrombolysis: evidence for a pharmacokinetic interaction.
    Kerins DM, Shuh M, Kunitada S, Fitzgerald GA, Fitzgerald DJ.
    J Pharmacol Exp Ther; 1991 Apr 28; 257(1):487-92. PubMed ID: 1708425
    [Abstract] [Full Text] [Related]

  • 15. Comparison of desulfatohirudin (REVASC) and heparin as adjuncts to thrombolytic therapy with reteplase in a canine model of coronary thrombosis.
    Martin U, Dörge L, Fischer S.
    Br J Pharmacol; 1996 May 28; 118(2):271-6. PubMed ID: 8735626
    [Abstract] [Full Text] [Related]

  • 16. Systemic lysis protects against the effects of platelet activation during coronary thrombolysis.
    Fitzgerald DJ, Hanson M, FitzGerald GA.
    J Clin Invest; 1991 Nov 28; 88(5):1589-95. PubMed ID: 1939647
    [Abstract] [Full Text] [Related]

  • 17. Reperfusion, specific thrombin inhibition and reocclusion after thrombolysis.
    Chesebro JH, Fuster V.
    J Am Coll Cardiol; 1990 Sep 28; 16(3):723-5. PubMed ID: 2117621
    [No Abstract] [Full Text] [Related]

  • 18. Coronary thrombosis/thrombolysis in pigs: effects of heparin, ASA, and the thrombin inhibitor inogatran.
    Uriuda Y, Wang QD, Hatori N, Nordlander R, Sjöquist PO, Mattsson C, Rydén L.
    J Pharmacol Toxicol Methods; 1998 Mar 28; 39(2):81-9. PubMed ID: 9694166
    [Abstract] [Full Text] [Related]

  • 19. Pathological basis of failure of concurrent glyceryl trinitrate therapy to improve efficacy of tissue type plasminogen activator in coronary thrombosis.
    Nicolini FA, Nichols WW, Saldeen TG, Mehta JL.
    Cardiovasc Res; 1991 Apr 28; 25(4):283-9. PubMed ID: 1909212
    [Abstract] [Full Text] [Related]

  • 20. In vivo thrombin inhibition enhances and sustains arterial recanalization with recombinant tissue-type plasminogen activator.
    Jang IK, Gold HK, Leinbach RC, Fallon JT, Collen D.
    Circ Res; 1990 Dec 28; 67(6):1552-61. PubMed ID: 2123135
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 9.